Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Thomas Jefferson University
With
National Institute on Drug Abuse (NIDA)
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 37 weeks gestation
exposure to opiates in utero
demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment
You may not be if
major congenital malformations and/or intrauterine growth retardation
medical illness requiring intensification of medical therapy
concomitant benzodiazepine or severe alcohol abuse, self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother during pregnancy,
concomitant use of CYP 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment
seizure activity or other neurologic abnormality
breast feeding
inability of mother to give informed consent due to co-morbid psychiatric diagnosis
hypoglycemia requiring treatment with intravenous glucose
Clareo Health | Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
